Pinealon (EDR): What the Khavinson Research Actually Shows
Pinealon is a Glu-Asp-Arg tripeptide from the Khavinson bioregulator programme. What the published work really demonstrates, what it does not, and why the doses circulating online are wrong.
This article covers Pinealon strictly as a laboratory research compound. It is not a medicine, not a supplement, and nothing below is a dosing recommendation or an instruction for human or animal use.
TL;DR: the short version
- Pinealon is a synthetic tripeptide, Glu-Asp-Arg (EDR), made in a lab, not extracted from a pineal gland and not a hormone the body already produces.
- The DNA-binding story is a proposed mechanism, built from cell-free assays and nuclear-localisation experiments, not a proven transcriptional switch inside a living neuron.
- The only published human dose is oral, in micrograms: 200 mcg per day by capsule, nowhere near the milligram figures quoted on vendor and forum pages.
- Almost the entire literature comes from one institute, much of it published in Russian-language journals, with no large randomised human trial and no marketing authorisation anywhere.
- We have no certificate of analysis for Pinealon yet, because no batch has arrived. That will be published before any batch goes on sale.
Short-peptide bioregulator (Glu-Asp-Arg, EDR) from the Khavinson programme, studied for gene-expression effects in neuronal tissue and for protection of nerve cells under stress. The brain-focused counterpart to Epitalon in the same cytogen series.
What Pinealon actually is
Pinealon is a synthetic tripeptide: three amino acids, glutamic acid, aspartic acid and arginine, joined in that order. Chemists shorten that to Glu-Asp-Arg, or, using single-letter amino acid codes, EDR, and in the literature the peptide is often referred to simply as EDR rather than by its full name.
It belongs to the short-peptide "bioregulator" research programme built over several decades by Vladimir Khavinson at the St Petersburg Institute of Bioregulation and Gerontology. The programme's central proposal is that peptides only 2 to 4 amino acids long, sometimes called cytogens in this literature, can act as tissue-selective regulators, meaning a peptide modelled on one tissue is proposed to influence gene expression in that tissue in a targeted way rather than acting as a broad, non-specific agent. Pinealon is the entry in that family generally studied in neuronal and central-nervous-system models.
That single sentence, "generally studied in neuronal models," is doing more work than it looks like. It is a description of which experiments researchers have chosen to run, not evidence of an approved use, a clinical indication, or a settled biological role. Keep that distinction in mind for everything that follows.
One more thing worth stating up front: the overwhelming majority of what has been published on Pinealon specifically comes from this one institute and its direct collaborators. That is not disqualifying on its own, but it does mean this article is describing what one research group, working from one integrated theory, has reported, rather than a broad, independently confirmed body of science. We will come back to why that matters.
Getting the family tree right: Pinealon, Epitalon, Thymalin
Three names get used almost interchangeably in secondary write-ups about this research programme, and they should not be.
Epitalon, sometimes spelled Epithalon, is Ala-Glu-Asp-Gly, AEDG, a four-amino-acid synthetic peptide from the same Khavinson programme, generally studied around the pineal gland, telomere-related endpoints and circadian markers. It shares an origin with Pinealon (same institute, same theoretical framework, both are synthetic peptides of one fully defined sequence) but it is a different molecule studied for different research questions. Nothing shown for Epitalon should be assumed to apply to Pinealon, or the other way round.
Thymalin is a different category of material entirely, and this is worth being blunt about because it gets blurred into the "short synthetic peptide" bucket constantly. Thymalin is a polypeptide complex extracted from calf thymus tissue. It does not have a single defined amino acid sequence the way Pinealon (EDR) or Epitalon (AEDG) do; it is a standardised mixture of naturally occurring thymic peptides, characterised by extraction method and biological activity rather than by one chemical structure. Calling Thymalin a "short peptide" alongside Pinealon and Epitalon is a category error. It is a tissue-extract complex, not a synthetic short peptide, and research findings on one class do not transfer to the other.
The proposed mechanism, and what was actually measured
The theoretical pitch behind the whole bioregulator programme is that a peptide this short, 2 to 4 residues, is small enough to cross the cell membrane and the nuclear membrane, and that once inside the nucleus it interacts with DNA in a way that shifts which genes get transcribed, in a tissue-selective manner. That is the proposed mechanism. It is a genuinely interesting question in basic peptide biology. It is not, on the currently available evidence, a demonstrated mechanism of action inside an intact, living cell.
What was observed versus what is proposed
Two separate kinds of experiment get cited together in support of this idea, and they are not the same experiment. Fluorescently labelled peptide has been detected inside the nucleus of HeLa cells, and, in a separate cell-free assay, the intact peptide has been shown to interact specifically with isolated oligonucleotides and DNA (PMID 22117547). A biophysical study has since examined how the EDR tripeptide interacts with DNA in solution and the role monovalent and divalent ions play in that interaction (PMID 30762356). A further cell-free biochemistry paper from the same laboratory looked at how short peptides interact with FITC-labelled histone proteins and their complexes with DNA oligonucleotides, extending the question from "does the peptide bind DNA" to "does it also interact with the proteins DNA is wrapped around" (PMID 23581987). None of these three papers shows the peptide binding chromatin inside a living neuron, and none establishes a causal chain from any binding event to a specific change in gene transcription. Nuclear localisation, DNA binding in a test tube, and histone interaction in a cell-free system are three separate, real observations. Stringing them into "it enters the nucleus and switches on genes" is an inference the published work does not close.
Put plainly: peptide detected inside a nucleus, yes. Peptide interacting with isolated DNA and with isolated histone proteins outside a cell, yes. Peptide demonstrably binding chromatin inside a living neuron and causally altering that neuron's transcription as a result, not shown by the papers available to us. That gap between what is proposed and what has actually been measured is the single most important thing to carry into the rest of this article.
The cell and animal record
Beneath the mechanism question sits a body of cell-culture and animal work, again concentrated almost entirely within the same programme.
In cultured neuronal cells, Pinealon has been reported to suppress free-radical (oxidative-stress) activity and to support cell viability and proliferation under experimental stress (PMID 21978084). In a mouse hippocampal neuron culture built to model amyloid synaptotoxicity, a feature of Alzheimer's-type pathology, a single treatment with the EDR tripeptide at 200 nanograms per millilitre increased the number of mature "mushroom" dendritic spines by 71 percent, returning that measure to a normal, untreated level (PMID 28853087). The same paper tested a related tripeptide, KED, under the same conditions and found a smaller, 20 percent increase, which is a useful reminder that even within this peptide family, sequence changes the size of the effect.
More recently, induced cortical neurons derived from aged human donors' skin cells were cultured with the EDR sequence added to the medium, with the paper reporting a protective effect against markers of age-related neuronal decline in that cell system (PMID 39518916). That is a 2024 addition to the literature and it uses human-derived cells, which sit closer to human biology than rodent cells, but it remains a laboratory cell-culture finding, not a study in a living person.
On the animal side, a rat model of prenatal hyperhomocysteinemia, elevated homocysteine during pregnancy induced by dietary methionine loading, administered Pinealon to the pregnant dams before the methionine loading, and then examined cognitive and neuroprotective outcomes in the offspring (PMID 22567179). A cluster of further rodent studies, mostly published in Uspekhi Gerontologii (Advances in Gerontology), looked at behaviour, hypoxia and markers of programmed cell death in older rats: one compared Pinealon and another peptide preparation across acute hypobaric hypoxia and mild hypothermia models (PMID 28509493), one examined effects on Morris-maze learning and caspase-3 activity in the brains of young and old rats (PMID 28976148), one looked at behaviour and caspase-3 activity following carotid artery occlusion in old rats (PMID 21809624), and one measured serum cytokines and brain caspase-3 activity in old rats under acute hypoxic stress (PMID 25051764). Review articles from within the same research tradition summarise the proposed gene-expression mechanism in the context of Alzheimer's disease pathology (PMID 33396470) and neuroprotective effects of peptide bioregulators across different age groups more broadly (PMID 24738258).
Read generously, this is a coherent, internally consistent preclinical picture: cell protection under oxidative and metabolic stress, a specific and fairly large structural recovery in a disease-relevant neuron model, and a set of animal behavioural and biochemical correlates that point in a similar direction. Read cautiously, and this is the more accurate framing given who generated it, it is cell-culture and rodent data, produced substantially by one research group starting from one theoretical model, without the kind of independent, multi-laboratory replication that would let anyone treat these findings as settled.
The dose question: what was actually given to humans
This is the part of the Pinealon conversation that gets handled least honestly online, so it is worth being unusually precise about it.
The only published human daily dose
In a two-week study of locomotive-brigade workers, a population studied in this research tradition for fatigue and stress-resilience markers, participants took one capsule containing 100 micrograms of Pinealon by mouth, twice a day, for a total oral intake of 200 micrograms (0.2 mg) per day (PMID 22708445). As far as the published record shows, that is the entire confirmed human daily dosing figure for Pinealon: 200 micrograms, taken orally, split into two 100-microgram capsules.
Beyond that pilot, a small number of further human reports exist. One describes 32 patients aged 41 to 83 with chronic polymorbidity, meaning several coexisting chronic conditions, and organic brain syndrome, in which 17 participants received Pinealon and 15 received a second cytogen from the same programme in separate groups, not in combination (PMID 26390612). Another compares outcomes across a broader set of geroprotective methods in a 110-patient cohort (PMID 28539017), and a related paper used a work-ability index as a way of assessing the geroprotective effect of small peptides in working adults (PMID 28509489). None of these three papers states a specific Pinealon dose in its abstract, so we are not going to manufacture one. What can honestly be said is that they exist, that they describe older or polymorbid populations, and that they add no additional, citable dosing figure beyond the 200-microgram oral pilot above.
That 200-microgram-per-day oral figure is, as far as the published record shows, the entire confirmed human dosing evidence base for Pinealon. It is nowhere near the milligram-per-day schedules that appear on vendor pages and forum threads, some of which describe doses many times higher, frequently by injection rather than by mouth. Those figures are not derived from the controlled research discussed above. We do not reproduce them, and we would treat any claim that they come from published research with real scepticism.
It is also worth separating form and route explicitly, because the two get conflated constantly. A 10 mg lyophilised vial intended for laboratory reconstitution describes a total peptide quantity and a research-use route, not an oral human dose. A vial's total content is not a "dose" in the sense the capsule study used that word, and a milligram vial figure and a microgram oral study figure are not interchangeable just because they name the same peptide.
How strong is this evidence, honestly
Zoom out, and this is a thin literature, thin in a specific, describable way rather than simply "not much has been published."
Nearly all of it originates from one institute and its direct collaborators, working from one integrated theory of short-peptide bioregulation. A large share of the underlying papers, including most of the animal work cited above, is published in Russian-language journals, which limits how easily the wider international research community can scrutinise, replicate or build on it. Independent replication by groups outside that tradition is limited. We are not aware of any large randomised controlled human trial of Pinealon, and Pinealon holds no marketing authorisation as a medicine anywhere.
None of that means the underlying biology is necessarily wrong. It means the confidence any careful reader should place in it should be calibrated to what a single-programme, largely regional, non-replicated evidence base actually supports: an interesting research lead worth further, better-controlled study, not an established, well-characterised human intervention. There is also no controlled human safety database of the kind regulatory trials generate for approved medicines. The absence of reported adverse effects in the small studies available is not evidence of safety. It mostly reflects the fact that the kind of large, properly monitored safety trials that would surface rare or delayed effects have simply not been run.
Why identity and purity matter more than usual here
For a compound with an evidence base this thin and this concentrated in one research tradition, knowing exactly what is in the vial matters more, not less. If the only real signal in the literature comes from small studies using one specific, well-characterised three-amino-acid sequence, then a research sample that is not that sequence, at the stated purity, does not just create a quality problem: it breaks the connection to whatever the published work does show.
We are not going to overstate our own position here either. We do not yet have a certificate of analysis for Pinealon, because no batch of it has arrived in our warehouse. Once a batch does arrive, it will carry the same documentation as every other product we sell: a batch-specific report from Janoshik, an independent analytical laboratory, commissioned through the supply chain rather than by us, published before the batch goes on sale. Until then, an absent Pinealon CoA on this site should be read as exactly what it is: a product that has not shipped yet, not a corner that has been cut.
Frequently asked questions
Related reading
Check current Pinealon batch status and specifications
Compare with Epitalon, the four-amino-acid peptide from the same programme
See Thymalin, the thymus-derived peptide complex, a different class of material
Mitochondrial function, NAD+ metabolism, telomere maintenance
This article is for informational and research purposes only. All products discussed are intended exclusively for in-vitro research and laboratory use, not for human consumption or ingestion. Pinealon is not an approved medicinal product, and nothing in this article constitutes a dosing recommendation.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include 19% VAT; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.